Home › Funds › RA CAPITAL MANAGEMENT, L.P. › CCCC

RA CAPITAL MANAGEMENT, L.P. position in CCCC

C4 THERAPEUTICS INC · Health Care

RA CAPITAL MANAGEMENT, L.P. reported holding 8,000,000 shares of CCCC (C4 THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$37.4M, representing 0.32% of its reported portfolio and ranking #46 among its reported holdings. RA CAPITAL MANAGEMENT, L.P. has disclosed CCCC holdings in 8 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)8.00M sh
Reported value held$37.36M
Portfolio Weight0.32%
First reportedQ4 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How RA CAPITAL MANAGEMENT, L.P.'s CCCC position evolved

RA CAPITAL MANAGEMENT, L.P. first disclosed a stake in CCCC in Q4 2023 at 4,878,000 shares (US$27.6M). The position peaked in Q1 2024 at 4,878,000 shares, worth US$39.9M. Across 8 filings, RA CAPITAL MANAGEMENT, L.P. held the position steady without any share-count change. The most recent filing (Q2 2026) shows 8,000,000 shares valued at US$37.4M.

Quarter by quarter

QuarterSharesValueChange
Q4 2023 4.88M $27.56M New
Q1 2024 4.88M $39.85M Hold
Q2 2024 4.88M $22.54M Hold
Q3 2024 4.88M $27.80M Hold
Q4 2024 4.88M $17.56M Hold
Q4 2025 8.00M $15.28M New
Q1 2026 8.00M $21.04M Hold
Q2 2026 8.00M $37.36M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About CCCC and 13F data

CCCC (C4 THERAPEUTICS INC) is a Health Care company. 51 other funds we track also report a position in CCCC — the largest reported positions include Lynx1 Capital Management LP (US$34.2M), Bain Capital Life Sciences Investors, LLC (US$33.5M), Soleus Capital Management, L.P. (US$15.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding CCCC

All CCCC fund holders →

FAQ

How long has RA CAPITAL MANAGEMENT, L.P. held CCCC?

RA CAPITAL MANAGEMENT, L.P. has disclosed CCCC holdings in 8 of the last 11 reported quarters, going back to Q4 2023.

What is RA CAPITAL MANAGEMENT, L.P.'s current position in CCCC?

As of Q2 2026, RA CAPITAL MANAGEMENT, L.P. holds 8.00M shares of CCCC (C4 THERAPEUTICS INC), valued at $37.36M, representing 0.32% of its reported portfolio and ranking #46.

Has RA CAPITAL MANAGEMENT, L.P. been buying or selling CCCC?

In the latest 13F filing (Q2 2026), RA CAPITAL MANAGEMENT, L.P. held unchanged its position in CCCC. The position peaked in Q1 2024 at 4.88M shares.

Which other funds hold CCCC?

Other major institutional holders of CCCC include Lynx1 Capital Management LP, Bain Capital Life Sciences Investors, LLC, Soleus Capital Management, L.P., among 51 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.